Author/Authors :
Shaei Huang، نويسنده , , Robert M. Garbaccio، نويسنده , , Mark E. Fraley، نويسنده , , Justin Steen، نويسنده , , Constantine Kreatsoulas، نويسنده , , George Hartman، نويسنده , , Steve Stirdivant، نويسنده , , Bob Drakas، نويسنده , , Keith Rickert، نويسنده , , Eileen Walsh-Greene، نويسنده , , Kelly Hamilton، نويسنده , , Carolyn A. Buser، نويسنده , , James Hardwick، نويسنده , , Xianzhi Mao، نويسنده , , Marc Abrams، نويسنده , , Steve Beck، نويسنده , , Weikang Tao، نويسنده , , Rob Lobell، نويسنده , , Laura Sepp-Lorenzino، نويسنده , , Youwei Yan، نويسنده , , et al.، نويسنده ,
Abstract :
Through a comparison of X-ray co-crystallographic data for 1 and 2 in the Chek1 active site, it was hypothesized that the affinity of the indolylquinolinone series (2) for Chek1 kinase would be improved via C6 substitution into the hydrophobic region I (HI) pocket. An efficient route to 6-bromo-3-indolyl-quinolinone (9) was developed, and this series was rapidly optimized for potency by modification at C6. A general trend was observed among these low nanomolar Chek1 inhibitors that compounds with multiple basic amines, or elevated polar surface area (PSA) exhibited poor cell potency. Minimization of these parameters (basic amines, PSA) resulted in Chek1 inhibitors with improved cell potency, and preliminary pharmacokinetic data are presented for several of these compounds.
Keywords :
quinolinone , PSA , Chek1 inhibitor , anticancer , p53 , Pharmacokinetics , Chekpoint escape , kinase , Chek1 , Indolylquinolinone